Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).
Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).
复制标题
DOI：
10.1007/978-1-0716-1433-4_12
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Portincasa P
中科院分区：
文献类型：
--
作者：
Grattagliano I;Di Ciaula A;Baj J;Molina-Molina E;Shanmugam H;Garruti G;Wang DQ;Portincasa P
非酒精性脂肪肝病（NAFLD）是发达国家最常见的代谢性慢性肝病之一，使人群面临发展为肝脏坏死炎症、纤维化、肝硬化和肝细胞癌的风险。线粒体功能障碍与 NAFLD 的发病有关，并导致 NAFLD 进展为非酒精性脂肪性肝炎 (NASH)。因此，肝线粒体可能成为改善 NAFLD 患者肝功能的治疗靶点。本章描述了 NAFLD 患者潜在治疗干预的最重要步骤，讨论了从实验和临床证据中收集的当前选择，并提出了一些可能改善 NAFLD 线粒体功能的新选择。
Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent metabolic chronic liver diseases in developed countries and puts the populations at risk of progression to liver necro-inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Mitochondrial dysfunction is involved in the onset of NAFLD and contributes to the progression from NAFLD to nonalcoholic steatohepatitis (NASH). Thus, liver mitochondria could become the target for treatments for improving liver function in NAFLD patients. This chapter describes the most important steps used for potential therapeutic interventions in NAFLD patients, discusses current options gathered from both experimental and clinical evidence, and presents some novel options for potentially improving mitochondrial function in NAFLD.